ForPatients
by Roche

Multiple Myeloma

A Dose-escalation Study to Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Trial Status	Trial Runs In	Trial Identifier
Recruiting	7 Countries	NCT05646836 2022-001204-18,2023-505212-38-00 GO43980

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and activity of XmAb24306 in combination with cevostamab in participants with relapsed/ refractory multiple myeloma (R/R MM) who have received a minimum of three prior treatments, including at least one immunomodulatory drug (IMiD), one proteasome inhibitor (PI), and one anti-CD38 monoclonal antibody.

Genentech, Inc.
Sponsor

Phase 1
Phase

NCT05646836 2022-001204-18,2023-505212-38-00 GO43980
Trial Identifiers

Eligibility Criteria:

Gender	Age	Healthy Volunteers
All	>=18 Years	No